Cargando…

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors

In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancini, Manuela, De Santis, Sara, Monaldi, Cecilia, Castagnetti, Fausto, Lonetti, Annalisa, Bruno, Samantha, Dan, Elisa, Sinigaglia, Barbara, Rosti, Gianantonio, Cavo, Michele, Gugliotta, Gabriele, Soverini, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391055/
https://www.ncbi.nlm.nih.gov/pubmed/35992847
http://dx.doi.org/10.3389/fonc.2022.901132
_version_ 1784770785334788096
author Mancini, Manuela
De Santis, Sara
Monaldi, Cecilia
Castagnetti, Fausto
Lonetti, Annalisa
Bruno, Samantha
Dan, Elisa
Sinigaglia, Barbara
Rosti, Gianantonio
Cavo, Michele
Gugliotta, Gabriele
Soverini, Simona
author_facet Mancini, Manuela
De Santis, Sara
Monaldi, Cecilia
Castagnetti, Fausto
Lonetti, Annalisa
Bruno, Samantha
Dan, Elisa
Sinigaglia, Barbara
Rosti, Gianantonio
Cavo, Michele
Gugliotta, Gabriele
Soverini, Simona
author_sort Mancini, Manuela
collection PubMed
description In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker γH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.
format Online
Article
Text
id pubmed-9391055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93910552022-08-20 Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors Mancini, Manuela De Santis, Sara Monaldi, Cecilia Castagnetti, Fausto Lonetti, Annalisa Bruno, Samantha Dan, Elisa Sinigaglia, Barbara Rosti, Gianantonio Cavo, Michele Gugliotta, Gabriele Soverini, Simona Front Oncol Oncology In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent resistance to the tyrosine kinase inhibitor (TKI) imatinib mesylate and in leukemic stem cell (LSC) persistence. It can be speculated that the observed deregulated activity of Aurora A and Plk1 enhances DNA damage, promoting the occurrence of additional genomic alterations contributing to TKI resistance and ultimately driving progression from chronic phase to blast crisis (BC). In this study, we propose a new therapeutic strategy based on the combination of Aurora kinase A or PLK1 inhibition with danusertib or volasertib, respectively, and WEE1 inhibition with AZD1775. Danusertib and volasertib used as single drugs induced apoptosis and G2/M-phase arrest, associated with accumulation of phospho-WEE1. Subsequent addition of the WEE1 inhibitor AZD1775 in combination significantly enhanced the induction of apoptotic cell death in TKI-sensitive and -resistant cell lines as compared to both danusertib and volasertib alone and to the simultaneous combination. This schedule indeed induced a significant increase of the DNA double-strand break marker γH2AX, forcing the cells through successive replication cycles ultimately resulting in apoptosis. Finally, combination of danusertib or volasertib+AZD1775 significantly reduced the clonogenic potential of CD34+ CML progenitors from BC patients. Our results may have implications for the development of innovative therapeutic approaches aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9391055/ /pubmed/35992847 http://dx.doi.org/10.3389/fonc.2022.901132 Text en Copyright © 2022 Mancini, De Santis, Monaldi, Castagnetti, Lonetti, Bruno, Dan, Sinigaglia, Rosti, Cavo, Gugliotta and Soverini https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mancini, Manuela
De Santis, Sara
Monaldi, Cecilia
Castagnetti, Fausto
Lonetti, Annalisa
Bruno, Samantha
Dan, Elisa
Sinigaglia, Barbara
Rosti, Gianantonio
Cavo, Michele
Gugliotta, Gabriele
Soverini, Simona
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
title Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
title_full Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
title_fullStr Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
title_full_unstemmed Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
title_short Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
title_sort polo-like kinase-1, aurora kinase a and wee1 kinase are promising druggable targets in cml cells displaying bcr::abl1-independent resistance to tyrosine kinase inhibitors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391055/
https://www.ncbi.nlm.nih.gov/pubmed/35992847
http://dx.doi.org/10.3389/fonc.2022.901132
work_keys_str_mv AT mancinimanuela pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT desantissara pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT monaldicecilia pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT castagnettifausto pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT lonettiannalisa pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT brunosamantha pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT danelisa pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT sinigagliabarbara pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT rostigianantonio pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT cavomichele pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT gugliottagabriele pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors
AT soverinisimona pololikekinase1aurorakinaseaandwee1kinasearepromisingdruggabletargetsincmlcellsdisplayingbcrabl1independentresistancetotyrosinekinaseinhibitors